Mission of our CDMO
Skyepharma is a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.
Our CDMO is specialized in oral solid forms. Our mission is to provide product development, manufacturing and packaging services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationship.
Our expert team
With about 35 years experience in pharmaceutial sector, Skyepharma employes about 200 specialists, including 1/4 in development department.
Our corporate culture is based on 3 main values:
Transparency
Excellence
Caring
Over the years we have also implemented several advanced governance practices as daily huddle and GEMBA Walk.
Our history
Through many years of involvement and achievements in the pharmaceutical industry, Skyepharma’s development and manufacturing facility is a leader in the field of classic and complex oral solid dosage forms.
1990 | Plant construction
Construction of the Saint-Quentin-Fallavier plant by the American laboratory Lederle, then a subsidiary of the American Cyanamid chemical group, now acquired by Pfizer. The site replaced the former Oullins (Rhône) plant.
1996 | SkyePharma plc establishment
Ian Gowrie-Smith, founder of Medeva, creates SkyePharma plc as a virtual entity. Skyepharma then acquires JAGO AG, small Swiss private company specialized in development, operating under that name before rebranding as Skyepharma AG two years later.
1997 | Skyepharma acquires Saint-Quentin-Fallavier plant
Skyepharma has subsequently invested in the site to adapt it to the production of modified-release tablets, particularly those using the patented Geomatrix® technology.
1998 | FDA certification
Skyepharma obtains FDA certification with the manufacturing of tablets using Geomatrix® technology for a US generic. In this period of time, Skyepharma also developed an mdDPI Foradil (formoterol) for Novartis that had been approved in more than 30 countries including the USA. The Saint-Quentin-Fallavier site ensured the filling of DPI until the product was withdrawn from the market.
1999-2000 | Development and Acquisitions
Skyepharma develops its business by acquiring several companies:
– The American company Depotech (San Diego), specialized in the development of sustained-release injectables, which became “Skyepharma Inc”.
– Bioglan Pharma (DK) and Hyal Pharmaceutical (Canada) Corporation, both specialized in topical products. Hyal originated Solaraze.
– The Montreal-based RTP pharma company that was the origin of Triglide.2011-2016 | Aenova
The Saint-Quentin-Fallavier site is under a management lease agreement with the German CMO Aenova. The owner being Skyepharma plc and the tenant Aenova. The activity is carried out under the name Aenova.
2016 | Acquisition by Vectura group
Following the 5-year lease management by Aenova, SkyePharma PLC merges with the Vectura group, an industry-leading inhaled respiratory disease-focused business . The inhaled activity of SkyePharma PLC is absorbed by Vectura and Skyepharma Production is created as an entity to perform Oral Business Unit activities.
2021 | Independent CDMO
Skyepharma becomes a newly independent CDMO.
2022 | Non-Sexual Hormones Development and Manufacturing
Opening of new contained area for Non-Sexual Hormones Production
2023 | Skyehub Construction
Skyepharma lauches its bioproduction activity and builds its very first Skyehub in partnership with MaaT Pharma.
2024 | Highly Potent API area opening
Skyepharma build its new segregated and contained area for highly potent medication (OEB4/5), such as oncology and immuno drug products.
2025 | Transition in Leadership and Shareholders
David Lescuyer handed over the leadership to Sébastien Mas, the new CEO of Skyepharma, while Bertrand Simon and Hervé Letoublon acquired 100% of the company’s capital through the Oleron Pharma holding, becoming Skyepharma’s new shareholders.
Our Leadership Team
Sébastien Mas, CEO
Industrial transformation and performance improvement expert with over 14 years of experience, Sébastien has a strong financial background and ensures the company’s continued growth while upholding Skyepharma’s core values: transparency, caring, and excellence.
Bertrand Simon, Shareholder
Founder of BYCap, a consultancy agency renowned for its expertise in business transmission and development operations, Bertrand acquired Skyepharma in 2025 to bring new energy, strategic development expertise, and a long-term vision for Skyepharma’s growth.
Hervé Letoublon (Jadel), Shareholder
Founder of Jadel (evergreen investment company : Patient Capital) and a capital-investment professional with over 20 years of experience, Hervé invests in Skyepharma for its strong positioning, scientific know-how, and solid worldwide reputation.
Ludivine Laugerette, Quality Director & Qualified Person Site
With a PharmD and a Master's in Medical Engineering, Pharmaceutical Development, and Production, Ludivine has over 10 years of experience in the pharmaceutical quality department, ensuring our quality system is flawless.
Chahrazed Derbal, Manufacturing Director
With over 30 years of experience in pharmaceutical manufacturing and strong expertise in solid dosage forms in particular, Chahrazed is the Head of the Manufacturing Department at Skyepharma, ensuring smooth and seamless operational processes.
Virginie Mattens, Head of Human Ressources
With over 10 years of experience in the pharmaceutical sector, Virginie manages the Human Resources Department at Skyepharma, ensuring that the corporate culture is upheld and that new talents are successfully integrated.
Our HSE engagement
At Skyepharma, safeguarding health, ensuring safety, and protecting the environment are at the heart of everything we do. We are committed to fostering a culture that prioritizes well-being, reduces risks, and promotes sustainability across all our operations.
Health
Regular medical check-ups and wellness programs ensure our teams’ physical and mental health.
Safety
We uphold strict safety standards through training, risk assessments, and regulatory compliance.
Environment
Committed to sustainability, we reduce waste, improve energy efficiency, and minimize our ecological footprint.